This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Antidepressants in Panic Disorder: Clinical and Preclinical Mechanisms

David J. Nutt, M.D., Ph.D.

Published: May 1, 1998

Article Abstract

Advances have been made in understanding the biology of panic disorder and the role of the underlyingserotonergic dysfunction. This review summarizes the biological evidence for the involvementof serotonin in the pathogenesis of panic disorder and considers the 2 opposing theories that are currentlyprevalent (5-HT excess and 5-HT deficit). The serotonin selective reuptake inhibitors are increasinglyconsidered as first-line treatment for panic disorder, and the interaction of these agents withthe serotonergic system is considered.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 59

Quick Links: